SECOND AMENDMENT OF SUBLICENSE AGREEMENT
Exhibit 10.3
SECOND AMENDMENT OF SUBLICENSE AGREEMENT
THIS
SECOND AMENDMENT OF SUBLICENSE AGREEMENT (this "First Amendment")
is executed as of January 26, 2021, by and between CGI Cellerate
RX, LLC, a Texas limited liability company, having its principle
place of business at 0000 Xxxxxx Xxxxxxxxx, Xxxxxxxx XX, Xxxxx 000,
Xxxxxx, XX 00000 (“Sublicensor”), and Cellerate, LLC,
a Texas limited liability company having its principal place of
business at 0000 Xxxxxx Xxxxxx, Xxxxx 000, Xxxx Xxxxx Xxxxx 00000,
(“Sublicensee”).
Sublicensor and Sublicensee are sometimes each referred to herein
as a “Party” and collectively, as the
“Parties
RECITALS
On
August 27, 2018, Sublicensor and Sublicensee entered into that
certain agreement whereby Sublicensor granted an exclusive,
non-revocable, transferrable right in and to the Licensed IP to
sell, export, market and distribute, Products for Wound Care
(including, without limitation, the Products listed on Schedule A
attached hereto) within the Territory in the Field of Use (the
“Sublicense”) to Sublicensee to be effective the 28th
day of August, 2018, (the “Effective Date”).
It is
mutually understood and agreed by and between the Parties that as
of this date Subsection 6.1 is changed to read as
follows:
6.1 Term.
The term of this Agreement commences on the Effective Date and
shall run until May 17, 2050 and then continue each Year thereafter
so long as Licensee's Net Sales each Year are equal to or in excess
of ONE MILLION DOLLARS ($1,000,000) (the "Term") unless terminated
sooner as set forth below. In the event Licensee's Net Sales fall
below ONE MILLION DOLLARS ($1,000,000) for any Year commencing
after May 17, 2050, then in such event, Licensor shall have the
right to terminate this Agreement upon written notice to the
Licensee.
All
other terms and conditions that are not hereby amended are to
remain in full force and effect.
CGI
Cellerate RX, LLC,
as
Sublicensor
By /s/ Xxxxxxx
Xxxxxxxx
Xxxx
Xxxxxxxx
Vice
President
CELLERATE,
LLC,
as
Sublicensee
By /s/ J. Xxxxxxx
Xxxxxxx
Xxxx
Xxxxxxx
President